



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/735,519	12/12/2003	Jacho Kim	GUID.160PA (03-512)	1580
51294	7590	10/13/2006	EXAMINER	
HOLLINGSWORTH & FUNK, LLC			KRAMER, NICOLE R	
8009 34TH AVE S.				
SUITE 125			ART UNIT	PAPER NUMBER
MINNEAPOLIS, MN 55425				3762

DATE MAILED: 10/13/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	10/735,519	KIM ET AL.
	Examiner Nicole R. Kramer	Art Unit 3762

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent-term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 11 September 2006.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-63 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 1-63 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All b) Some * c) None of:
1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date <u>6/8/06</u> . | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Double Patenting

1. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

2. Claims 24, 28, 38, 41, and 56 stand provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claim 11 of copending Application No. 10/734,599. Although the conflicting claims are not identical, they are not patentably distinct from each other because both claims require delivering a pacing pulse using one electrode configuration, sensing a cardiac signal after delivery of the pacing pulse using a different electrode configuration, establishing or defining a plurality of classification windows, and classifying the cardiac response based on a detected characteristic of the cardiac signal.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

3. Claims 24-34, 38, 41, and 56 stand provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-94 of copending Application No. 10/733,869. Although the conflicting claims are not identical, they are not patentably distinct from each other because both claims require delivering a pacing pulse, sensing a cardiac signal after delivery of the pacing pulse, establishing or defining a plurality of classification windows, and classifying the cardiac response based on a detected characteristic of the cardiac signal. The claims of the '869 application do not require that the sensing a cardiac signal use a second or different electrode configuration than the configuration used for delivering a pacing pulse. It would have been obvious to modify the method/apparatus claimed in the '869 patent such that sensing a cardiac signal uses a second or different electrode configuration than the configuration used for delivering a pacing pulse in order to verify whether a pacing pulse delivered in one heart chamber is captured in another heart chamber.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Claim Rejections - 35 USC § 102

4. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

5. Claims 1, 3-4, 6, 8-9, 11-12, 15, 17-30, 32, 34-39, 41-42, 45-47, 52, 55-57, 79, and 61-62 stand rejected under 35 U.S.C. 102(b) as being anticipated by U.S. Patent No. 6,456,881 ("Bornzin et al.").

Bornzin et al. discloses a method (method 300 illustrated in Fig. 3) for determining a cardiac response to a pacing pulse, which is implemented whenever microcontroller 60 performs capture verification in either or both the right and left ventricles (see col. 7, lines 17-40). A ventricular stimulation pacing pulse is delivered to the heart at step 305 (see col. 7, lines 40-45) using a first electrode combination (the ventricular stimulation pulse is necessarily delivered using either coronary sinus lead 24 or right ventricular lead 30; see col. 5, line 58 - col. 6, line 28). After the pacing pulse is delivered, a single atrial EGM is sensed for cardiac response classification (see col. 7, lines 45-54) using a second electrode combination (the atrial signal is sensed using right the tip electrode 22 of atrial lead 20 and the pacemaker housing, or using ring electrode 27 of coronary sinus lead 24 and the pacemaker housing; see col. 8, lines 9-20); and classifying the cardiac response to the pacing pulse as one of a captured response, a non-captured response, and a fusion beat based on the sensed cardiac

signal (at decision steps 332, 335, and 325 of Fig. 3, fusion, loss of capture, or capture is confirmed by examining the atrial sensed signal sensed at step 330; see col. 8, line 21 - col. 9, line 30).

With respect to claims 3, 4, 6, 8, 22, and 36, Bornzin et al. discloses that classifying the cardiac response comprises comparing a detected signal characteristic to a reference (the atrial sensed signal is examined to determine if a far-field R-wave signal is detected; see col. 8, line 45 - col. 9, line 5. Bornzin et al. incorporates by reference patent application 09/946,614, entitled "System and Method for Ventricular Capture using Far Field Evoked Response", filed Dec. 14, 1999, which Examiner believes was intended to recite U.S. Patent No. 6,345,201, entitled "System and Method for Ventricular Capture using Far Field Evoked Response", filed Dec. 14, 1999. The '201 patent describes that the far-field signal sensed by the atrial channel is sampled to determine its amplitude; see col. 8, lines 39-41. The FFR sample is compared to a predetermined far-field signal recognition template to verify whether the FFR sample morphology corresponds to a far-field R-wave that is expected to follow a captured ventricular stimulation pulse; see col. 5, lines 30-42 and col. 8, lines 41-50). The cardiac response is classified based on the comparison (if no FFR is detected, loss of capture is confirmed as described at col. 9, lines 8-9. If FFR is detected, then fusion is confirmed as described at col. 9, lines 23-24).

With respect to claims 9, 23, 37, 42, and 55, the pacing pulse is delivered using a near field vector (the ventricular stimulation pulse is necessarily delivered using either coronary sinus lead 24 or right ventricular lead 30; see col. 5, line 58 - col. 6, line 28),

and the atrial cardiac signal is sensed using a far-field vector (the atrial signal is sensed using right the tip electrode 22 of atrial lead 20 and the pacemaker housing, or using ring electrode 27 of coronary sinus lead 24 and the pacemaker housing; see col. 8, lines 9-20).

With respect to claims 11-12 and 47, Bornzin et al. further teaches that as part of classifying the cardiac responses, the ventricular EGM is sampled from the ventricular chamber in which stimulation is applied, which could be the left ventricle, the right ventricle, or both the left and right ventricles (see col. 7, lines 45-55). The ventricular signal may be sensed using various electrode configurations, such as between the tip electrode and the can, the ring electrode and the can, the tip electrode and the ring electrode, the coronary sinus electrode 27 and the tip electrode, etc... (see col. 7, line 55 - col. 8, line 8). The ventricular EGM is used to determine if the evoked response resulted in capture (see col. 8, lines 21-42).

With respect to claims 45-46, Bornzin et al. discloses that the ventricular stimulation may be applied within the left ventricle, the right ventricle, or both (see col. 7, lines 45-55). Further, Bornzin et al. discloses that either the right or left atrial EGM signal may be used to classify the cardiac response (see col. 8, lines 9-20).

With respect to claims 20 and 21, Bornzin et al. explicitly discloses classifying the cardiac response to the pacing pulse as one of a captured response, a non-captured response, and a fusion beat using the sensed cardiac signal (at decision steps 332, 335, and 325 of Fig. 3, fusion, loss of capture, or capture is confirmed by examining the atrial sensed signal sensed at step 330; see col. 8, line 21 - col. 9, line 30). Examiner

Art Unit: 3762

considers classification of a captured response in Bornzin et al. to necessarily include classification of a near non-captured response, because both responses result in a captured stimulation pulse. Further, Examiner considers classification of non-captured response in Bornzin et al. to necessarily include a non-captured response added to an intrinsic beat, because both responses result in a non-captured, stimulation pulse.

With respect to claims 24, 28-30, 32, 34, 38, 41, and 56, Bornzin et al. discloses that immediately after the Vpulse, the atrial and ventricular EGMS are sampled and stored for a predefined time such as 50-100 msec (see col. 7, lines 46-54). Microcontroller 60 first determines if an evoked response is detected from the sampled ventricular sample in order to see if capture is confirmed (see col. 8, lines 21-42). If capture is not confirmed, microcontroller 60 samples the atrial sensed signal to determine if a FFR signal was detected to confirm either fusion or loss of capture (see col. 8, line 43 - col. 9, line 30). Examiner considers these decision steps (i.e., sampling of the cardiac signals, examination of the ventricular signal, examination of the atrial signal) to be "a plurality of classification windows relative to and subsequent to the pacing pulse." A characteristic of the cardiac signal is detected within a particular classification window (the atrial sensed signal is examined to determine if a far-field R-wave signal is detected; see col. 8, line 45 - col. 9, line 5. Bornzin et al. incorporates by reference patent application 09/946,614, entitled "System and Method for Ventricular Capture using Far Field Evoked Response", filed Dec. 14, 1999, which Examiner believes was intended to recite U.S. Patent No. 6,345,201, entitled "System and Method for Ventricular Capture using Far Field Evoked Response", filed Dec. 14, 1999. The

'201 patent describes that the far-field signal sensed by the atrial channel is sampled to determine its amplitude; see col. 8, lines 39-41. The FFR sample is compared to a predetermined far-field signal recognition template to verify whether the FFR sample morphology corresponds to a far-field R-wave that is expected to follow a captured ventricular stimulation pulse; see col. 5, lines 30-42 and col. 8, lines 41-50); and the cardiac response to the pacing pulse is classified based on the detected characteristic and the particular classification window (if no FFR is detected, loss of capture is confirmed as described at col. 9, lines 8-9. If FFR is detected, then fusion is confirmed as described at col. 9, lines 23-24).

With respect to claims 57-62, Examiner notes that Applicant has invoked 112, sixth paragraph. Examiner considers the "means for" performing the recited claim elements to be equivalent to the means disclosed in Bornzin et al. (such as the leads, electrodes, and sensing circuitry, and pulse generators for pacing and sensing cardiac signals as described at col. 5, line 50 - col. 6, line 50; and a microcontroller 60 for classifying the cardiac responses as described at col. 7, lines 16-40).

Claim Rejections - 35 USC § 103

6. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

- (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

7. Claims 2, 16, 40, 53, 58, and 60 stand rejected under 35 U.S.C. 103(a) as being unpatentable over U.S. Patent No. 6,456,881 ("Bornzin et al."), as applied above, in view of U.S. Patent No. 5,522,860 ("Molin et al.").

Bornzin et al. teaches that the microcontroller 60 includes timing circuitry for keeping track of noise detection windows (see col. 10, lines 57-64), but fails to explicitly disclose that if noise is detected on the cardiac signal, the classification of the cardiac response is canceled. Molin et al. teaches that it is well known in the art to determine the presence of noise, and suspend a function of the device if there is too much noise (see Abstract). It would have been obvious to one having ordinary skill in the art at the time of applicant's invention to modify the method of identifying fusion as disclosed in Bornzin et al. such that if noise is detected on the cardiac signal, the classification of the cardiac response is canceled/suspended as taught by Molin et al. in order to avoid classifying cardiac signals which contain too much noise (which would necessarily lead to an improper classification and therefore may lead to an improper response/therapy being delivered).

8. Claims 5, 7, 31, and 33 stand rejected under 35 U.S.C. 103(a) as being unpatentable over U.S. Patent No. 6,456,881 ("Bornzin et al.") in view of U.S. Patent No. 6,738,669 ("Sloman et al.").

As described above, Bornzin et al. discloses that the atrial sensed signal is examined to determine if a far-field R-wave signal is detected; see col. 8, line 45 - col. 9, line 5. Bornzin et al. incorporates by reference patent application 09/946,614, entitled

"System and Method for Ventricular Capture using Far Field Evoked Response", filed Dec. 14, 1999, which Examiner believes was intended to recite U.S. Patent No. 6,345,201, entitled "System and Method for Ventricular Capture using Far Field Evoked Response", filed Dec. 14, 1999. The '201 patent describes that the far-field signal sensed by the atrial channel is sampled to determine its amplitude; see col. 8, lines 39-41. The FFR sample is compared to a predetermined far-field signal recognition template to verify whether the FFR sample morphology corresponds to a far-field R-wave that is expected to follow a captured ventricular stimulation pulse; see col. 5, lines 30-42 and col. 8, lines 41-50. Bornzin et al. fails to disclose that detecting the characteristic comprises detecting a slope or pulse width of the cardiac signal and comparing the detected characteristic to a reference comprises comparing the detected slope/pulse width to a slope/pulse width reference. Sloman et al. teaches that there are many standard methods known in the art for comparing various features of an evoked R-wave to an expected value to determine if the sampled far-field signal is indeed a far-field R-wave, such as peak amplitude, the integral, the slope, the morphology, or another characteristic feature (see col. 12, lines 50-60). It would have been obvious to one having ordinary skill in the art at the time of applicant's invention to modify the method of identifying fusion as disclosed in Bornzin et al. such that slope and/or pulse width is utilized for determining if the sampled far-field signal is indeed a far-field R-wave as taught by Sloman et al. in order to effectively identify a far-field R-wave by standard, known methods in the art.

Further, Examiner notes that it would have been an obvious matter of design choice to utilize any characteristic feature of the evoked R-wave, including the slope or pulse width, for determining if the sampled far-field signal is indeed a far-field R-wave, since applicant has not disclosed that utilizing the slope or pulse width solves any stated problem or is for any particular purpose, and it appears that the claimed invention would perform equally well with utilizing the amplitude and morphology of the evoked R-wave as disclosed in Bornzin et al.

9. Claims 10, 43, 44, 54, and 63 stand rejected under 35 U.S.C. 103(a) as being unpatentable over U.S. Patent No. 6,456,881 ("Bornzin et al.").

As discussed above, Bornzin et al. discloses that a ventricular stimulation pacing pulse is delivered to the heart at step 305 (see col. 7, lines 40-45) using a first electrode combination (the ventricular stimulation pulse is necessarily delivered using either coronary sinus lead 24 or right ventricular lead 30; see col. 5, line 58 - col. 6, line 28). Examiner considers the structure utilized for delivering the ventricular pulse to be a "rate channel vector" because such ventricular stimulation pulses necessarily control the delivered rate. After the pacing pulse is delivered, the atrial EGM is sensed (see col. 7, lines 45-54) using a second electrode combination (the atrial signal is sensed using right the tip electrode 22 of atrial lead 20 and the pacemaker housing, or using ring electrode 27 of coronary sinus lead 24 and the pacemaker housing; see col. 8, lines 9-20). Since Bornzin et al. does not explicitly disclose that atrial coil electrode 28, which is used for shocking therapy (see col. 6, lines 3-14), may be used for sensing the atrial

signal, Bornzin et al. fails to disclose that a shock channel vector may be utilized for sensing the cardiac signal. However, it is well known in the art that a shock channel vector may be used to sense a cardiac signal. It would have been an obvious matter of design choice to utilize coil electrode 28 for sensing the far-field atrial signal, since applicant has not disclosed that utilizing a shock channel vector solves any stated problem or is for any particular purpose, and it appears that the claimed invention would perform equally well with utilizing any electrode which detects the far-field atrial signal.

See MPEP 2144.04 and 2144.06-2144.07.

With respect to claims 44 and 63, Bornzin et al. further teaches that as part of classifying the cardiac responses, the ventricular EGM is sampled from the ventricular chamber in which stimulation is applied, which could be the left ventricle, the right ventricle, or both the left and right ventricles (see col. 7, lines 45-55). The ventricular signal may be sensed using various electrode configurations, such as between the tip electrode and the can, the ring electrode and the can, the tip electrode and the ring electrode, the coronary sinus electrode 27 and the tip electrode, etc... (see col. 7, line 55 - col. 8, line 8). The ventricular EGM is used to determine if the evoked response resulted in capture (see col. 8, lines 21-42). Bornzin et al. does not explicitly disclose that the coil electrode may be used for sensing the ventricular signal. However, it is well known in the art that a shock channel vector may be used to sense a cardiac signal. It would have been an obvious matter of design choice to utilize the coil electrode for sensing the ventricular signal, since applicant has not disclosed that utilizing the coil electrode solves any stated problem or is for any particular purpose, and it appears that

the claimed invention would perform equally well with utilizing any electrode which detects the ventricular signal. See MPEP 2144.04 and 2144.06-2144.07.

10. Claims 13-14 and 48 stand rejected under 35 U.S.C. 103(a) as being unpatentable over U.S. Patent No. 6,456,881 ("Bornzin et al.") in view of U.S. Patent No. 6,434,428 ("Sloman et al").

Bornzin et al. discloses a method for ventricular capture verification, in which stimulation pulses are applied to one or both of the ventricles, and the atrial EGM signal is used for distinguishing loss of capture from fusion (see col. 7, line 16 - col. 9, line 30). Bornzin et al. fails to disclose that the methodology for verifying capture may be used in an atrial capture verification test, in which the pacing pulse is delivered to an atrium. Sloman et al. discloses an atrial verification test in which a stimulation pulse is delivered to the atrium, and the atrial lead is used for sensing a far-field signal which distinguishes capture from non-capture (see col. 10, line 54 - col. 12, line 11). It would have been obvious to one having ordinary skill in the art at the time of applicant's invention to modify the method of identifying fusion as disclosed in Bornzin et al. such that the stimulation pulse is delivered to an atrium such that the sensed cardiac signal can be used to verify atrial capture as well as ventricular capture.

11. Claims 50-51 stand rejected under 35 U.S.C. 103(a) as being unpatentable over U.S. Patent No. 6,456,881 ("Bornzin et al.") in view of U.S. Patent No. 4,878,497 ("Callaghan et al.").

Bornzin et al. fails to disclose that the pulse delivery circuit further comprises a coupling capacitor through which the pacing pulse is delivered. Callaghan et al. teaches a pacemaker for distinguishing between a fusion beat and loss of capture, in which the pulse delivery circuit further comprises a coupling capacitor through which the pacing pulse is delivered (see col. 5, lines 5-15, which describe that output coupling capacitor 60 is utilized for delivering the electrical charge in order to quickly diminish the post-stimulus polarization of the electrode). It would have been obvious to one having ordinary skill in the art at the time of applicant's invention to modify the system for identifying fusion as disclosed in Bornzin et al. to include a coupling capacitor as taught by Callaghan et al. in order to quickly diminish the post-stimulus polarization of the electrode.

With respect to claim 51, it would have been obvious to one having ordinary skill in the art at the time of applicant's invention for the coupling capacitor to have a range of about 2 microfarads to about 22 microfarads, since it has been held that where the general conditions of a claim are disclosed in the prior art, discovering the optimum or workable ranges involves only routine skill in the art. See, for example, *In re Aller*, 105 USPQ 233.

Response to Arguments

12. Applicant's arguments filed 9/11/2006 have been fully considered but they are not persuasive.

13. In particular, Applicant argues that the independent claims have been amended to explicitly require that the approach for discriminating between different types of cardiac pacing responses or detecting fusion is based on a *single cardiac single* sensed from a vector that is different from the pacing vector (that is, sensed from a different, second electrode combination than the electrode combination used to deliver a pacing pulse). In contrast, Applicant argues that Bornzin teaches a 2-channel approach for discriminating between fusion and non-capture - if the ventricular channel indicates non-capture, the atrial channel is analyzed to classify the cardiac response (see page 18 of Response filed 9/11/06).

Examiner respectfully disagrees that the amendment overcomes Bornzin for two reasons. In a first respect, the amendment does not result in the claim scope that is argued by the applicant. The amendment simply requires that a second electrode combination is used to sense "a single cardiac signal for cardiac response classification." Examiner considers the sensed atrial EGM of Bornzin to be such a "single cardiac single" since only one, single atrial EGM is sensed in Bornzin and that signal is used for cardiac response classification (see col. 7, lines 45-54). Although Bornzin senses a ventricular EGM signal to initially confirm whether capture has occurred (see col. 8, lines 21-42), this ventricular EGM is not sensed using the second electrode combination - it is sensed using the first electrode combination (see col. 7, lines 49-54). In addition, the claim amendment further requires that the classification step be based on the single, sensed cardiac signal. With respect to this claim limitation, Bornzin uses the atrial signal to classify the response as fusion, loss of capture, or

capture (see decision steps 332, 335, 325, 330 of Fig. 3; see also col. 8, line 21 - col. 9, line 30). Examiner notes that the claim amendment does not require such classification to be based solely on the single cardiac signal - the classification must only be based at least partially on the single, cardiac signal.

In addition, even if the claim amendment resulted in the claim scope argued by the applicant (that is, assuming that the claim required the classification be based solely on the sensed, single cardiac signal), Examiner still disagrees that the amendment overcomes Bornzin. As apparent from Figure 3 of Bornzin, the atrial signal alone is the signal that used to distinguish whether the cardiac response is fusion or loss of capture (at decision steps 332, 335, and 325 of Fig. 3, fusion, loss of capture, or capture is confirmed by examining the atrial sensed signal sensed at step 330; see col. 8, line 21 - col. 9, line 30). While it is true that the ventricular EGM is initially examined to confirm whether capture has occurred (see col. 8, lines 21-42), it is examination of the atrial signal that is used to detect whether fusion has occurred (see col. 8, line 43 - col. 9, line 30).

14. Applicant also notes with respect to claims 10, 43, 44, and 54, that Applicant is not required to state an advantage for each feature recited in the claims (see page 19 of Response filed 9/11/06). Examiner agrees that Applicant is not required to state an advantage for each feature recited in the claims. However, Examiner notes that according to the MPEP, if the applicant has demonstrated the criticality of a specific limitation, it would not be appropriate to rely solely on case law as the rationale to

support an obviousness rejection. See MPEP 2144.04. Even if substituting known equivalents is the basis for the rejection (as above) rather than case law, Examiner reviews the specification to determine whether applicant has demonstrated the criticality of a specific limitation before applying an obvious-type, design choice rejection. The obvious-type, design choice rejection is based on the observation that it is well known in the art to utilize the shock channel or coil electrodes for sensing a cardiac signal, and it appears that the claimed invention would perform equally well with utilizing any electrode configuration that detects the ventricular signal or far-field atrial signal. It does not appear that there is any criticality to using the shock channel or coil electrodes for sensing the cardiac response signal in the present application.

Applicant further states that the specification discloses various advantages for the use of the shock channel or coil electrodes for sensing by pointing out the discussion relating to temporal separation of the cardiac response signal and the pacing artifact signal that can be achieved using various electrodes (see page 20 of Response filed 9/11/06). However, this discussion relates to advantages of utilizing various electrode configurations in general for sensing and pacing - it does not specifically discuss advantages for the use of the shock channel or coil electrodes for sensing. Bornzin et al. utilizes a first electrode configuration for the delivering the pacing pace (the ventricular stimulation pulse is delivered using either coronary sinus lead 24 or right ventricular lead 30; see col. 5, line 58 - col. 6, line 28) and a second, separate electrode configuration for sensing the cardiac response signal (the atrial EGM is sensed using right the tip electrode 22 of atrial lead 20 and the pacemaker housing, or using ring

electrode 27 of coronary sinus lead 24 and the pacemaker housing; see col. 8, lines 9-20). Utilizing such different electrode configurations necessarily result in temporal separation of the cardiac response signal and the pacing artifact signal.

Conclusion

15. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Nicole R. Kramer whose telephone number is 571-272-8792. The examiner can normally be reached on Monday through Friday, 8 a.m. to 4:30 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Angela Sykes can be reached on 571-272-4955. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

NRK

NRK

10/10/06


George Manuel
Primary Examiner